Year of primary qualification: 2008
Current institution: Academic Medical Centre, Amsterdam, The Netherlands
Title of presentation: Evidence-based guideline recommendations on cytoreductive surgery and HIPEC for peritoneal carcinomatosis of colorectal cancer origin (New Trials Forum: Guidelines synthesis)
Learning objectives: The objective of this presentation is to provide an overview of excisting national guidelines on CR/HIPEC treatment for colorectal cancer. Details of a systematic search for relevant guidelines, quality criteria of the content of the identified guidelines, topics that are addressed, and the scientific background of recommendations will be presented. Main topics in this field include diagnostic work-up, patient selection for CR/HIPEC, and methodology of the HIPEC procedure. Discrepancies among countries will be discussed, with issues that may be explored by future research projects.
Clinical/research background
Since 2010, consultant gastrointestinal and oncologic surgeon at the AMC in Amsterdam, with clinical focus on colorectal and liver surgery. PhD thesis in 2002 on sentinel node biopsy in breast and penile carcinoma. Since 2005, research focus on colorectal cancer. Principle investigator of the BIOPEX study (multicentre RCT, biomesh following ELAPE) and COLOPEC study (multicentre RCT, adjuvant HIPEC T4 colon cancer). Member of the national colorectal cancer guideline committee. Secretary of the Dutch Colorectal Cancer Group. Associate Editor of Colorectal Disease and Digestive Surgery. Member of the scientific committee of the Dutch Surgical Colorectal Audit.
Relevant peer-reviewed publications
- Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, Aalbers AG, van der Bilt JD, Boerma D, Bremers AJ, Burger JW, Buskens CJ, Evers P, van Ginkel RJ, van Grevenstein WM, Hemmer PH, de Hingh IH, Lammers LA, van Leeuwen BL, Meijerink WJ, Nienhuijs SW, Pon J, Radema SA, van Ramshorst B, Snaebjornsson P, Tuynman JB, Te Velde EA, Wiezer MJ, de Wilt JH, Tanis PJ. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428.
- Sloothaak DA, Gardenbroek TJ, Crezee J, Bemelman WA, Punt CJ, Buskens CJ, Tanis PJ. Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. Eur J Surg Oncol. 2014;40:1453-8.
- Sloothaak DA, Mirck B, Punt CJ, Bemelman WA, van der Bilt JD, D'Hoore A, Tanis PJ. Intraperitoneal chemotherapy as adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis.
Information submitted for ESCP Dublin 2015